BMS-184476 Bristol-Myers Squibb.
BMS-184476 is a taxane analog under development by Bristol-Myers Squibb for the potential treatment of solid tumors. By February 2001, it had entered phase II trials and, as of May 2002, phase II studies had been carried out in patients with a number of tumor types, including breast, ovarian and non-small-cell lung cancer.
Ojima
Iwao
I
Department of Chemistry, Institute of Chemical Biology and Drug Discovery, State University of New York at Stony Brook, Stony Brook, NY 11794-3400, USA. iojima@notes.cc.sunysb.edu
Geney
Raphaël
R
D000818:Animals; D017322:Clinical Trials, Phase II as Topic / Q000706:statistics & numerical data; D015507:Drugs, Investigational / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D009369:Neoplasms / Q000188:drug therapy / Q000378:metabolism; D017239:Paclitaxel / Q000031:analogs & derivatives* / Q000737:chemistry / Q000493:pharmacokinetics / Q000627:therapeutic use*; D043823:Taxoids; D013678:Technology, Pharmaceutical / Q000379:methods*
D015507:Drugs, Investigational; D043823:Taxoids; C426424:7-methylthiomethylpaclitaxel; D017239:Paclitaxel